Elrig

MARCH 25, 2025

Prof Rory Johnson is an Associate Professor at University College Dublin, where his research focusses on uncovering the roles of long noncoding RNAs (lncRNAs) in human health and disease using an interdisciplinary combination of bioinformatic and experimental methods.

RNA 59

RNA Bioinformatics Science Pharmacokinetics 59

Drug Target Review

JULY 12, 2023

Omics data, including pharmacogenomics data from 3D-TGAs, provide us with unique information about the molecular mechanisms of disease biology and drug response. Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Practical Cheminformatics

JANUARY 8, 2024

GPT-4 could provide the sequence and binding sites for the SARS-CoV-2 main protease, but this information can also be readily accessed through the PDB. The responses seemed more like a “ stochastic parrot ” that could grab information and key phrases from online documents. First, summarization and information retrieval.

Drugs 136

Drugs Small Molecule Bioinformatics Packaging 136

DrugBank

FEBRUARY 12, 2025

This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Pharma Data

JULY 27, 2021

. “Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. ” In June 2021, AbbVie Inc.

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

OCTOBER 27, 2020

Medtronic continues to work toward satisfying these conditions, but in December 2019 , due to FDA communications, Medtronic informed us that these conditions will not be satisfied in 2020. In October 2020 , we completed a second clinical study in healthy volunteers to compare the pharmacokinetics of Treprostinil Technosphere to Tyvaso.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

SEPTEMBER 1, 2020

Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Biomarkers and Bioinformatics. IMPORTANT SAFETY INFORMATION. For additional safety information, please see the full. Prescribing Information.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52